From the clinical perspective, GRP78 protein levels in plasma of bone marrow do not differ between primary and refractory MM and GRP78 cannot be used as biomarker to monitor disease progression or destruction of the bone microenvironment by MM cells. Here, HSPA5 is linked to Miyoshi myopathy.